Table 1.
Demographic characteristics and details of COVID‐19 in vaccinated individuals
| Demographic characteristics of all vaccine recipients (n = 1500) | ||
|---|---|---|
| Male, female | 1028, 472 | |
| Age (years) (mean ± SD) | 38.8 ± 12.8 | |
| Diabetes mellitus, n (%) | 142 (9.5) | |
| Hypertension, n (%) | 170 (11.3) | |
| Heart diseases, n (%) | CAD: 21 (1.4) | |
| RHD: 1 (0.1) | ||
| ASD: 1 (0.1) | ||
| Hypothyroidism, n (%) | 54 (3.6) | |
| Respiratory diseases, n (%) | Asthma/COPD: 41 (2.7) | |
|
ILD: 1 (0.1) |
||
| Characteristics of COVID‐19 (n = 1500) | ||
|---|---|---|
| Participants who received single dose of vaccine (n = 65) | Participants who received both doses of vaccine (n = 1435) | |
| Confirmed or suspect cases, n (%) | 30 (46.1) | 388 (27) |
| ≤14 days after second dose: n = 31 | ||
| >14 days after second dose: n = 357 | ||
| RT‐PCR confirmed SARS‐CoV‐2 infections | 27 (41.5) | 271 (18.9) |
| COVID‐19 suspect (not tested)a | 2 (3.1) | 82 (5.7) |
| RT‐PCR negative COVID‐19 suspectb | 1 (1.5) |
35 (2.4) |
| Efficacy (two doses of vaccine vs. single dose) against confirmed or suspect COVID‐19 |
41.3% |
|
| Severityc (all confirmed or suspect) | (n = 30) | (n = 388) |
| Asymptomatic | 1 (3.3) | 18 (4.6) |
| Mild | 21 (70) | 331 (85.3) |
| Moderate | 5 (16.7) | 33 (8.5) |
| Severe | 2 (6.7), including one death | 6 (1.5) |
| Unsure of severity | 1 (3.3), one death (other cause) |
– |
| Efficacy (Two doses of vaccine vs. one dose) against severe COVID‐19 |
86.4% |
|
| Hospitalization needed | 3 (all for oxygen requirement) | 19 (6 for oxygen requirement, 12 for observation, 1 for general caregiver support) |
| Median time of onset following vaccine dose in days (Q1,Q3; range) | 45 (29,55; 1–73) | 39 (28,47; 0–99) |
| Death due to other cause | 1 |
2 |
| Characteristics of COVID‐19 in doctors (n = 404) | ||
|---|---|---|
| Doctors who received single dose (n = 27) | Doctors who received both doses (n = 377) | |
| Confirmed or suspect cases, n (%) | 19 (70.4) | 160 (42.4) |
| ≤14 days after second dose: n = 12 | ||
| >14 days after second dose: n = 148 | ||
| RT‐PCR confirmed SARS‐CoV‐2 infections | 18 (66.7) | 131 (34.7) |
| COVID‐19 suspect (not tested)a | 0 (0) | 17 (4.5) |
| RT‐PCR negative COVID‐19 suspectb | 1 (3.7) |
12 (3.2) |
| Severityc (all confirmed or suspect) | (n = 19) | (n = 160) |
| Asymptomatic | 1 (5.3) | 9 (5.6) |
| Mild | 14 (73.7) | 130 (81.3) |
| Moderate | 3 (15.8) | 16 (10) |
| Severe | 1 (5.3) |
5 (3.1) |
| Hospitalization needed | 1 (for oxygen requirement) | 13 (5 for oxygen requirement, 7 for observation, 1 for general caregiver support) |
| Death due to other cause | 0 | 1 |
Note: COVID‐19 suspect cases are those in whom the investigators suspected COVID‐19 based on a clinical pattern of symptoms, exposure to confirmed/probable cases of COVID‐19 within the past 14 days, and general guidance from the clinical guidelines issued by the Ministry of Health and Family Welfare (MoHFW), Government of India. They were divided into: aCOVID‐19 suspect (not tested)—in the absence of rapid antigen test or RT‐PCR test report; bRT‐PCR negative COVID‐19 suspect—with a negative RT‐PCR test report; cas defined by the MoHFW, Government of India (for severity, all percentages are out of a total of confirmed and suspect infections).
Abbreviations: ASD, atrial septal defect; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; RHD, rheumatic heart disease; RT‐PCR, reverse‐transcriptase polymerase chain reaction.